Lung Cancer
Conditions
Brief summary
Patients (pts) with stage IIIA/IIIB NSCLC received NVBiv 25 mg/m² + CDDP 80 mg/m² on D1 and NVBo 60 mg/m² on D8 every 3 weeks (q3w) for 2 cycles as induction. Pts with response or non change received NVBo 20 mg fixed dose on D1 D3 D5 + CDDP 80 mg/m² on D1 q3w for 2 more cycles during RT(66 Gy/6.5 w).
Detailed description
Vinorelbine (NVB) + CDDP is considered a standard trt in induction or concomitantly with RT (Vokes, Fournel, Krzakowski). NVBo simplifies the administration of trt and provides the same efficacy as intravenous NVB (NVBiv). In order to assess this and to improve the tolerance, a trial was started with NVBiv and NVBo + CDDP as induction followed by a fractionated administration of NVBo + CDDP during RT.
Interventions
DRUGVinorelbine cisplatin radiotherapy
During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8. Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy).
Sponsors
Pierre Fabre Medicament
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* histologically or cytologically confirmed stage IIIA (only N2), * dry IIIB previously untreated inoperable NSCLC, * 18 to 75 years old, * Karnofsky Performance Status (KPS) ≥ 80%, * weight loss ≤ 10% within the previous 3 months, * normal organ functions were eligible. * at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) \[10\].
Exclusion criteria
* stages I, II, IIIA (excepted N2), IIIB with pleural effucion and stage IV, * pregnant or breastfeeding women. Women of Childbearing Age: Women of childbearing potential should take reliable contraceptive measures * Symptomatic Neuropathy \> grade 1, * associated Pathology and/or not controled diseases(cardiac insuficiency, myocardial infarction within 3 months before the inclusion ; hypertension, arythmia or uncontroled hypercalcémia; infection requiering iv antibiotic administration within 2 weeks before inculion), * other associated cancer with the exception of cervical carcinoma in situ or skin cancer baso-cellular correctely treated, * Previous treatment with an other antineoplasic, * Known hypersensibility to drugs with a similar chemical structure ti this studied. * important malabsorbtion syndrom or disease of gastro-intestinal track, * Participation to another clinical trial within 30 days before inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease controle | up to 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| - duration of response (DR) | up to 3 years | Secondary endpoints were duration of response (DR), progression-free survival (PFS), and overall survival (OS), calculated by the Kaplan-Meier method. The safety analysis reported the worst grade of the adverse events (NCI CTC v. 2.0) for the safety population. |
Other
| Measure | Time frame |
|---|---|
| - progression-free survival (PFS) | up to 3 years |
| - overall survival (OS), | up to 3 years |
| - safety | up to 3 years |
Countries
France
Outcome results
None listed